Kyverna Therapeutics Appoints Biotech Veterans Andrew Miller and Sravan Emany to Board
Summary
Kyverna Therapeutics appointed two highly experienced biotech and financial leaders to its Board of Directors, strengthening its strategic and operational capabilities for future growth and commercialization.
Key Events
-
Andrew Miller Appointed Director
Dr. Andrew Miller, founder of Karuna Therapeutics (acquired for $14B by Bristol Myers Squibb), was appointed as a Class III director, bringing extensive experience in biotech leadership, drug development, and corporate strategy. He will serve on the Science and Technology and Audit Committees.
-
Sravan Emany Appointed Director & Audit Committee Chair
Mr. Sravan Emany, current CFO of Beam Therapeutics and former CFO/COO of Ironwood Pharmaceuticals, was appointed as a Class I director and Chair of the Audit Committee. He contributes significant expertise in capital markets, M&A, and scaling rare disease companies.
-
Daniel Spiegelman Resigns from Board
Daniel Spiegelman resigned from the Board and its committees, effective February 24, 2026. The company stated his resignation was not due to any disagreement with the company's operations, policies, or practices.
Analysis
Kyverna Therapeutics has significantly strengthened its Board of Directors with the appointment of two highly experienced leaders. Dr. Andrew Miller brings a strong track record in drug development and corporate strategy, having founded Karuna Therapeutics, which was acquired for $14 billion. Mr. Sravan Emany, current CFO of Beam Therapeutics and former CFO/COO of Ironwood Pharmaceuticals, adds deep expertise in capital markets, M&A, and commercial-stage rare disease companies. These appointments are crucial for a clinical-stage biopharmaceutical company like Kyverna as it advances its pipeline towards potential commercialization and manages its recent $105 million capital raise. The non-contentious resignation of Daniel Spiegelman facilitates this strategic board refresh.
At the time of this filing, KYTX was trading at $7.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $451.9M. The 52-week trading range was $1.78 to $13.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.